What kind of drug is orelabrutinib?

Orelabrutinib is a small-molecule targeted drug classified as a Bruton's tyrosine kinase (BTK) inhibitor. It is mainly indicated for the treatment of specific types of B-cell malignancies, such as mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, etc.